The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jul. 16, 2019
Filed:
Dec. 15, 2016
Precedo Pharmaceuticals Co., Ltd, Hefei, Anhui, CN;
Jing Liu, Anhui, CN;
Qingsong Liu, Anhui, CN;
Taoshan Jiang, Anhui, CN;
Aoli Wang, Anhui, CN;
Jiaxin Wu, Anhui, CN;
Hong Wu, Anhui, CN;
Ziping Qi, Anhui, CN;
Yongfei Chen, Anhui, CN;
Fengming Zou, Anhui, CN;
Wenchao Wang, Anhui, CN;
Zheng Zhao, Anhui, CN;
Li Wang, Anhui, CN;
Beilei Wang, Anhui, CN;
PRECEDO PHARMACEUTICALS CO., LTD, Hefei, Anhui, CN;
Abstract
The present application provides a compound of formula I, which is a EGFR and ALK dual inhibitor and can be used alone or in combination with other therapeutic agents to treat diseases such as non-small cell lung cancer. The compounds of the present application are useful in the treatment of diseases carrying the EGFR wild-type gene, or carrying the EGFR T790M mutant gene and/or the EGFR L858R mutant gene and/or the EGFR delE746_A750 mutant gene, or in the treatment of diseases carrying the ALK wild-type gene, ALK F1174L mutant gene and/or ALK F1196M gene and/or EML4-ALK mutant gene and/or NPM-ALK mutant gene, and can be used in the first-line treatment of anaplastic lymphoma kinase (ALK) positive late-stage non-small cell Lung cancer.